Fractyl Health (GUTS) EBITDA Margin (2023 - 2024)
Fractyl Health's (GUTS) quarterly EBITDA Margin came in at 840333.33% in Q4 2024, down 65489048.0% YoY from N/an in Q1 2024, and down 394.44% on a QoQ basis from 169957.14% in Q3 2024.
Fractyl Health (GUTS) EBITDA Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of EBITDA Margin data on file, last reported at 840333.33% in Q4 2024.
- Quarterly EBITDA Margin fell 65489048.0% year-over-year to 840333.33% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 100570.97% (down 5820763.0% YoY) and the FY2024 annual result came in at 100570.97%, down 5820763.0% from the prior year.
- EBITDA Margin fell to 840333.33% in Q4 2024, from 169957.14% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 16493.06% in Q2 2023 to a low of 840333.33% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Fractyl Health | 109.12 Mn | 109.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -840,333.33% |
| Sep 30, 2024 | -169,957.14% |
| Jun 30, 2024 | -53,453.49% |
| Mar 31, 2024 | -65,278.79% |
| Dec 31, 2023 | -185,442.86% |
| Sep 30, 2023 | -38,536.11% |
| Jun 30, 2023 | -16,493.06% |
| Mar 31, 2023 | -242,140.00% |